https://pittplusme.org/study/1538
A Study to Evaluate Risankizumab in Participants with Moderate to Severe Atopic Dermatitis
We're sorry. This study is closed and no longer recruiting participants.
STUDY BASICS
Have you been diagnosed with moderate-to-severe atopic dermatitis (eczema) for at least the past 2 years? If so, you may be eligible to participate in a study of an investigational drug called risankizumab in subjects with atopic dermatitis. Involves 11 visits over up to 65 weeks. Compensation is provided.
IRB: Pro00034451
- AbbVie, Inc. - M16-813, A Phase 2, Multicenter, Randomized, Placebo- Controlled, Double-Blind Study to Evaluate Risankizumab in Adult and Adolescent Subjects with Moderate to Severe Atopic Dermatitis (Pro00034451)
AGE:
18 and up
DURATION:
Up to 65 weeks
VISITS:
11 visits & 1 phone call
LOCATION:
Falk Medical Building - Oakland
COMPENSATION:
$78.00 per visit & travel reimbursement
SHARE STUDY
MEET THE RESEARCHER
Laura Ferris
Laura Korb Ferris, MD, PhD, is Professor of Dermatology at the University of Pittsburgh School of Medicine, and is also the Director of Clinical Trials for the Department of Dermatology. Dr. Ferris earned her doctorate in immunology from Johns Hopkins University and her medical degree from the University of Maryland.